Ownership Capital B.V. Trims Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Ownership Capital B.V. decreased its position in DexCom, Inc. (NASDAQ:DXCM) by 7.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 701,971 shares of the medical device company’s stock after selling 59,839 shares during the period. DexCom accounts for approximately 2.0% of Ownership Capital B.V.’s investment portfolio, making the stock its 20th largest position. Ownership Capital B.V.’s holdings in DexCom were worth $54,592,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Versant Capital Management Inc purchased a new position in DexCom in the fourth quarter worth approximately $25,000. Heck Capital Advisors LLC purchased a new position in shares of DexCom during the 4th quarter worth $38,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of DexCom during the 3rd quarter worth about $57,000. Covestor Ltd raised its holdings in DexCom by 53.7% in the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after buying an additional 335 shares during the period. Finally, MassMutual Private Wealth & Trust FSB lifted its position in DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after buying an additional 265 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Price Performance

DexCom stock opened at $89.68 on Thursday. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The company has a fifty day simple moving average of $83.06 and a 200-day simple moving average of $75.85. The stock has a market cap of $35.03 billion, a P/E ratio of 62.71, a price-to-earnings-growth ratio of 2.31 and a beta of 1.14. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities analysts expect that DexCom, Inc. will post 1.98 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,083 shares of company stock valued at $3,309,794. 0.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

DXCM has been the subject of a number of recent analyst reports. Sanford C. Bernstein lifted their price target on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Wells Fargo & Company lifted their target price on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Oppenheimer cut their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Canaccord Genuity Group raised their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Finally, Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and an average target price of $99.06.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.